Systemic Delivery of an Adjuvant CXCR4–CXCL12 Signaling Inhibitor Encapsulated in Synthetic Protein Nanoparticles for Glioma Immunotherapy
Authors:
- 26 May 2022
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 16 (6) , 8729-8750
Abstract
Glioblastoma (GBM) is an aggressive primary brain cancer; with a 5-year survival of ~5%. Challenges that hamper GBM therapeutic efficacy include: (i) tumor heterogeneity, (ii) treatment resistance, (iii) immunosuppressive tumor microenvironment (TME) and (iv) the blood-brain barrier (BBB). The C-X-C Motif Chemokine Ligand-12/ C-X-C Motif Chemokine Receptor-4 (CXCL12/CXCR4) signaling pathway is activated in GBM and is associated with tumor progression. Although the CXCR4 antagonist (AMD3100) has been proposed as an attractive anti-GBM therapeutic target, it’s poor pharmacokinetic properties, and unfavorable bioavailability have hampered its clinical implementation. Thus, we developed synthetic protein nanoparticles (SPNPs) coated with the transcytotic peptide iRGD (AMD3100-SPNPs) to target the CXCL2/CXCR4 pathway in GBM via systemic delivery. We showed that AMD3100-SPNPs block CXCL12/CXCR4 signaling in three mouse and human GBM cell cultures in vitro and in a GBM mouse model in vivo. This results in (i) inhibition of GBM proliferation, (ii) reduced infiltration of CXCR4+ monocytic myeloid derived suppressor cells (M-MDSCs) into the TME, (iii) restoration of BBB integrity, and (iv) induction of immunogenic cell death (ICD), sensitizing the tumor to radiotherapy, and leading to anti-GBM immunity. Additionally, we showed that combining AMD3100-SPNPs with radiation led to long term survival; with ~60% of GBM tumor bearing mice remaining tumor free, after rechallenging with a second GBM in the contralateral hemisphere. This was due to a sustained anti-GBM immunological memory response that prevented tumor recurrence without additional treatment. In view of the potent ICD induction and reprogrammed tumor microenvironment, this SPNP-mediated strategy has a significant clinical translation applicability.Keywords
Funding Information
- Ian's Friends Foundation
- National Cancer Institute (F31CA247104, R01- CA243916)
- National Institute of Neurological Disorders and Stroke (R01-NS076991, R01-NS082311, R01-NS096756, R01-NS105556, R01-NS122536, R01-NS124167, R01NS122234, R21- NS123879-01, R37-NS094804)
- Agencia Nacional de Promoci?n Cient?fica y Tecnol?gica (PICT-2018-3088, PICT-2019-00117)
- Instituto Nacional del C?ncer
- ChadTough Foundation
- Pediatric Brain Tumor Foundation
- Forbes Foundation
- Smiles for Sophie Forever Foundation
- Rogel Cancer Center, University of Michigan
- Leah?s Happy Hearts Foundation
This publication has 61 references indexed in Scilit:
- Glioblastoma Multiforme Therapy and Mechanisms of ResistancePharmaceuticals, 2013
- Coadministration of a Tumor-Penetrating Peptide Enhances the Efficacy of Cancer DrugsScience, 2010
- Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in miceJournal of Clinical Investigation, 2010
- Tissue-Penetrating Delivery of Compounds and Nanoparticles into TumorsCancer Cell, 2009
- SDF-1α G801A Polymorphism Predicts Lymph Node Metastasis in Stage T3 Colorectal CancerAnnals of Surgical Oncology, 2009
- The immunogenicity of tumor cell deathCurrent Opinion in Oncology, 2009
- Calreticulin exposure is required for the immunogenicity of γ-irradiation and UVC light-induced apoptosisCell Death & Differentiation, 2007
- Functional expression of chemokine receptor CXCR4 on human epithelial cellsImmunology, 1999
- Estimation of the number of α‐helical and β‐strand segments in proteins using circular dichroism spectroscopyProtein Science, 1999
- Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar developmentNature, 1998